Literature DB >> 25210168

Early preservation of CXCR5+ PD-1+ helper T cells and B cell activation predict the breadth of neutralizing antibody responses in chronic HIV-1 infection.

Kristen Cohen1, Marcus Altfeld2, Galit Alter3, Leonidas Stamatatos4.   

Abstract

UNLABELLED: Much is known about the characteristics of broadly neutralizing antibodies (bNAbs) generated during HIV-1 infection, but little is known about immunological mechanisms responsible for their development in only a minority of those infected by HIV-1. By monitoring longitudinally a cohort of HIV-1-infected subjects, we observed that the preservation of CXCR5(+) CD4(+) T helper cell frequencies and activation status of B cells during the first year of infection correlates with the maximum breadth of plasma neutralizing antibody responses during chronic infection independently of viral load. Although, during the first year of infection, no differences were observed in the abilities of peripheral CXCR5(+) CD4(+) T helper cells to induce antibody secretion by autologous naive B cells, higher frequencies of class-switched antibodies were detected in cocultures of CXCR5(+) CD4(+) T and B cells from the subjects who later developed broadly neutralizing antibody responses than those who did not. Furthermore, B cells from the former subjects had higher expression of AICDA than B cells from the latter subjects, and transcript levels correlated with the frequency of CXCR5(+) CD4(+) T cells. Thus, the early preservation of CXCR5(+) CD4(+) T cells and B cell function are central to the development of bNAbs. Our study provides a possible explanation for their infrequent generation during HIV-1 infection. IMPORTANCE: Broadly neutralizing antibodies are developed by HIV-1-infected subjects, but so far (and despite intensive efforts over the past 3 decades) they have not been elicited by immunization. Understanding how bNAbs are generated during natural HIV-1 infection and why only some HIV-1-infected subjects generate such antibodies will assist our efforts to elicit bNAbs by immunization. CXCR5(+) PD-1(+) CD4(+) T cells are critical for the development of high-affinity antigen-specific antibody responses. In our study, we found that the HIV-1-infected subjects who develop bNAbs have a higher frequency of peripheral CXCR5(+) PD-1(+) CD4(+) T cells in early infection and also that this frequency mirrored what was observed in uninfected subjects and correlated with the level of B cell activation across subjects. Our study highlights the critical role helper T cell function has in the elicitation of broadly neutralizing antibody responses in the context of HIV infection.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25210168      PMCID: PMC4249103          DOI: 10.1128/JVI.02186-14

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  67 in total

Review 1.  Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates.

Authors:  Barton F Haynes; David C Montefiori
Journal:  Expert Rev Vaccines       Date:  2006-08       Impact factor: 5.217

2.  The transcriptional repressor Bcl-6 directs T follicular helper cell lineage commitment.

Authors:  Di Yu; Sudha Rao; Louis M Tsai; Sau K Lee; Yiqing He; Elissa L Sutcliffe; Monika Srivastava; Michelle Linterman; Lei Zheng; Nicholas Simpson; Julia I Ellyard; Ian A Parish; Cindy S Ma; Qi-Jing Li; Christopher R Parish; Charles R Mackay; Carola G Vinuesa
Journal:  Immunity       Date:  2009-07-23       Impact factor: 31.745

3.  In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10.

Authors:  Amapola Manrique; Peter Rusert; Beda Joos; Marek Fischer; Herbert Kuster; Christine Leemann; Barbara Niederöst; Rainer Weber; Gabriela Stiegler; Hermann Katinger; Huldrych F Günthard; Alexandra Trkola
Journal:  J Virol       Date:  2007-06-13       Impact factor: 5.103

4.  Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C.

Authors:  James M Binley; Elizabeth A Lybarger; Emma T Crooks; Michael S Seaman; Elin Gray; Katie L Davis; Julie M Decker; Diane Wycuff; Linda Harris; Natalie Hawkins; Blake Wood; Cory Nathe; Douglas Richman; Georgia D Tomaras; Frederic Bibollet-Ruche; James E Robinson; Lynn Morris; George M Shaw; David C Montefiori; John R Mascola
Journal:  J Virol       Date:  2008-09-24       Impact factor: 5.103

5.  Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection.

Authors:  D Noah Sather; Jakob Armann; Lance K Ching; Angeliki Mavrantoni; George Sellhorn; Zachary Caldwell; Xuesong Yu; Blake Wood; Steve Self; Spyros Kalams; Leonidas Stamatatos
Journal:  J Virol       Date:  2008-11-05       Impact factor: 5.103

6.  Bcl6 mediates the development of T follicular helper cells.

Authors:  Roza I Nurieva; Yeonseok Chung; Gustavo J Martinez; Xuexian O Yang; Shinya Tanaka; Tatyana D Matskevitch; Yi-Hong Wang; Chen Dong
Journal:  Science       Date:  2009-07-23       Impact factor: 47.728

7.  Altered expression of the receptor-ligand pair CXCR5/CXCL13 in B cells during chronic HIV-1 infection.

Authors:  Alberto Cagigi; Frida Mowafi; Linh V Phuong Dang; Klara Tenner-Racz; Ann Atlas; Sven Grutzmeier; Paul Racz; Francesca Chiodi; Anna Nilsson
Journal:  Blood       Date:  2008-09-09       Impact factor: 22.113

8.  Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies.

Authors:  Nicole A Doria-Rose; Rachel M Klein; Maura M Manion; Sijy O'Dell; Adhuna Phogat; Bimal Chakrabarti; Claire W Hallahan; Stephen A Migueles; Jens Wrammert; Rafi Ahmed; Martha Nason; Richard T Wyatt; John R Mascola; Mark Connors
Journal:  J Virol       Date:  2008-10-15       Impact factor: 5.103

9.  Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm.

Authors:  Melissa D Simek; Wasima Rida; Frances H Priddy; Pham Pung; Emily Carrow; Dagna S Laufer; Jennifer K Lehrman; Mark Boaz; Tony Tarragona-Fiol; George Miiro; Josephine Birungi; Anton Pozniak; Dale A McPhee; Olivier Manigart; Etienne Karita; André Inwoley; Walter Jaoko; Jack Dehovitz; Linda-Gail Bekker; Punnee Pitisuttithum; Robert Paris; Laura M Walker; Pascal Poignard; Terri Wrin; Patricia E Fast; Dennis R Burton; Wayne C Koff
Journal:  J Virol       Date:  2009-05-13       Impact factor: 5.103

10.  Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers.

Authors:  Ann J Hessell; Eva G Rakasz; Pascal Poignard; Lars Hangartner; Gary Landucci; Donald N Forthal; Wayne C Koff; David I Watkins; Dennis R Burton
Journal:  PLoS Pathog       Date:  2009-05-15       Impact factor: 6.823

View more
  49 in total

1.  Frequencies of Circulating Th1-Biased T Follicular Helper Cells in Acute HIV-1 Infection Correlate with the Development of HIV-Specific Antibody Responses and Lower Set Point Viral Load.

Authors:  Omolara Baiyegunhi; Bongiwe Ndlovu; Funsho Ogunshola; Nasreen Ismail; Bruce D Walker; Thumbi Ndung'u; Zaza M Ndhlovu
Journal:  J Virol       Date:  2018-07-17       Impact factor: 5.103

2.  CXCL13 is a plasma biomarker of germinal center activity.

Authors:  Colin Havenar-Daughton; Madelene Lindqvist; Antje Heit; Jennifer E Wu; Samantha M Reiss; Kayla Kendric; Simon Bélanger; Sudhir Pai Kasturi; Elise Landais; Rama S Akondy; Helen M McGuire; Marcella Bothwell; Parsia A Vagefi; Eileen Scully; Georgia D Tomaras; Mark M Davis; Pascal Poignard; Rafi Ahmed; Bruce D Walker; Bali Pulendran; M Juliana McElrath; Daniel E Kaufmann; Shane Crotty
Journal:  Proc Natl Acad Sci U S A       Date:  2016-02-23       Impact factor: 11.205

Review 3.  The Neutralizing Antibody Response to the HIV-1 Env Protein.

Authors:  Penny L Moore
Journal:  Curr HIV Res       Date:  2018       Impact factor: 1.581

4.  Envelope characteristics in individuals who developed neutralizing antibodies targeting different epitopes in HIV-1 subtype C infection.

Authors:  Bongiwe Ndlovu; Kamini Gounder; Daniel Muema; Nagarajan Raju; Tandile Hermanus; Qiniso Mthethwa; Kim Robertson; Bruce D Walker; Ivelin S Georgiev; Lynn Morris; Penny L Moore; Thumbi Ndung'u
Journal:  Virology       Date:  2020-03-25       Impact factor: 3.616

5.  Analysis of protective immune responses to seasonal influenza vaccination in HIV-infected individuals.

Authors:  Ying Xia; Fuli Mi; Guoqiang Du; Shenghui Qin
Journal:  Hum Vaccin Immunother       Date:  2020-05-15       Impact factor: 3.452

Review 6.  B-cell responses to HIV infection.

Authors:  Susan Moir; Anthony S Fauci
Journal:  Immunol Rev       Date:  2017-01       Impact factor: 12.988

7.  Detection of Broadly Neutralizing Activity within the First Months of HIV-1 Infection.

Authors:  V Sanchez-Merino; A Fabra-Garcia; N Gonzalez; D Nicolas; A Merino-Mansilla; C Manzardo; J Ambrosioni; A Schultz; A Meyerhans; J R Mascola; J M Gatell; J Alcami; J M Miro; E Yuste
Journal:  J Virol       Date:  2016-05-12       Impact factor: 5.103

8.  Early HIV infection is associated with reduced proportions of gamma delta T subsets as well as high creatinine and urea levels.

Authors:  Babatunde A Olusola; Dieter Kabelitz; David O Olaleye; Georgina N Odaibo
Journal:  Scand J Immunol       Date:  2020-02-19       Impact factor: 3.487

9.  HIV-1 Antibody Neutralization Breadth Is Associated with Enhanced HIV-Specific CD4+ T Cell Responses.

Authors:  Srinika Ranasinghe; Damien Z Soghoian; Madelene Lindqvist; Musie Ghebremichael; Faith Donaghey; Mary Carrington; Michael S Seaman; Daniel E Kaufmann; Bruce D Walker; Filippos Porichis
Journal:  J Virol       Date:  2015-12-09       Impact factor: 5.103

10.  Chronic HIV-1 Infection Impairs Superantigen-Induced Activation of Peripheral CD4+CXCR5+PD-1+ Cells, With Relative Preservation of Recall Antigen-Specific Responses.

Authors:  Katherine J Nicholas; David K Flaherty; Rita M Smith; D Noah Sather; Spyros A Kalams
Journal:  J Acquir Immune Defic Syndr       Date:  2017-01-01       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.